Malin has announced the appointment of Bahija Jallal as Immunocore chief executive officer and director of the board.
Bahija joins from AstraZeneca, where she was president and head of its global biologics research and development unit, MedImmune. She was a member of the senior executive team at AstraZeneca, reporting to the CEO. During her time at MedImmune, she oversaw significant growth in the AstraZeneca biologics pipeline across a range of disease areas.
“Bahija Jallal’s appointment as CEO of Immunocore strengthens the company’s management team and signals that it is entering a period of significant clinical and commercial maturity,” said Jean-Michel Cossery, non-executive director of Malin and Malin’s Immunocore Board designate.
“With significant leadership experience and an impressive scientific pedigree, she is ideally suited to lead Immunocore at this exciting time as it focuses on the approaching Biologics License Application submission for its lead asset, IMCgp100 and progressing its broad pipeline.”